French biotechnology company PathoQuest has received CE mark for its iDTECT blood test for clinical identification of pathogens from blood samples.

The iDTECT blood test represents a next generation sequencing (NGS)-based metagenomics approach which has been developed to provide a clinically improved method of detection of bacteria and viruses in blood samples derived from patients suspected with infections or immunocompromised patients.

Hôpital Necker-Enfants Malades infectious and tropical diseases department chair and professor Olivier Lortholary said: “In some clinical situations, especially when a patient is immunocompromised, culture and PCR tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy.

"CE marking of the iDTECT Blood test is a major milestone for PathoQuest."

“With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals (Paris, France) on a cohort of over 100 immuno-compromised patients.”

The iDTECT blood test uses PathoQuest’s proprietary methods to prepare blood samples and analyse it by leveraging the latest NGS-based technology to identify genomic sequences of pathogens in patient’s blood.

The genomic sequences, after being identified, are then compared to a comprehensive and curated database developed by PathoQuest which features genomics sequences from over 1,200 bacteria and viruses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PathoQuest CEO Jean-Francois Brepson said: “CE marking of the iDTECT Blood test is a major milestone for PathoQuest.

“It validates the robustness of our sample-to-BioIT analysis solution, driven by PathoQuest’s proprietary iDTECT database and software.”